Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 18

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 18
---
 calendar days, it would provide a detailed official hold letter and requested that the Company hold its response until after receipt
of such letter (the “Hold Letter”). The Company received the Hold Letter on July 26, 2024 and submitted a complete response
letter to the FDA on October 21, 2024 in which the Company requested a meeting to address the FDA’s questions. On November 15,
2024 the Company received notice from the FDA that the IND for CER-1236 was cleared. The Company continues to believe that we will be
able to initiate the planned clinical trial by early 2025.

Nasdaq Letters

On July 19, 2024, we received
a letter (the “Bid Price Requirement Letter”) from the staff at Nasdaq notifying us that, for the 30 consecutive trading
days prior to the date of the Bid Price Requirement Letter, the closing bid price for CERo Common Stock has been below the minimum $1.00
per share required for continued listing on Nasdaq set forth in Nasdaq Listing Rule 5450(a)(1), which is required for continued listing
of the Common Stock on Nasdaq (the “Bid Price Requirement”). On October 23, 2024, the trading price for CERo Common Stock
closed under $0.10 and was the tenth consecutive trading day to do so. On October 24, 2024, the Company received a letter from the staff
at The Nasdaq Global Market (“Nasdaq”) notifying the Company that, because its Common Stock had a closing bid price of $0.10
or less for ten consecutive trading days, it was no longer eligible to rely upon the 180-day cure period set forth in the Bid Price Requirement
Letter. In addition, on October 30, 2024, the Company received a letter from the staff at Nasdaq notifying the Company that it had not
regained compliance with the continued listing requirement to maintain a minimum market value of $50,000,000 for its listed securities
within the 180-day compliance period granted by Nasdaq in May 2024.

On July 19, 2024, we also
received a letter (the “MVPHS Letter” and together with the Bid Price Requirement Letter, the “Nasdaq Letters”)
from Nasdaq notifying us that the “Market Value of Publicly Held Shares” (the “MVPHS”) of our Common Stock had
been below the minimum of